Kidney Research Institute, Renal Division, West China Hospital of Sichuan University, Chengdu, People's Republic of China; Section of Nephrology, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France; CNRS, ERL 8228, Laboratoire de Physiologie Rénale et Tubulopathies, Paris, France.
Am J Kidney Dis. 2023 Apr;81(4):394-405. doi: 10.1053/j.ajkd.2022.09.010. Epub 2022 Nov 7.
RATIONALE & OBJECTIVES: The urine-to-plasma (U/P) ratio of urea is correlated with urine-concentrating capacity and associated with progression of autosomal dominant polycystic kidney disease. As a proposed biomarker of tubular function, we hypothesized that the U/P urea ratio would also be associated with progression of more common forms of chronic kidney disease (CKD).
Observational cohort study.
SETTING & PARTICIPANTS: 3,723 adults in the United States with estimated glomerular filtration rate (eGFR) of 20-70 mL/min/1.73 m, enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study.
U/P urea ratio, calculated from 24-hour urine collections and plasma samples at baseline.
Associations of U/P urea ratio with eGFR slope, initiation of kidney replacement therapy (KRT), and CKD progression, defined as 50% decline in eGFR or incident KRT.
Multivariable linear mixed-effects models tested associations with eGFR slope. Cox proportional hazards models tested associations with dichotomous CKD outcomes.
The median U/P urea ratio was 14.8 (IQR, 9.5-22.2). Compared with participants in the highest U/P urea ratio quintile, those in the lowest quintile had a greater eGFR decline by 1.06 mL/min/1.73 m per year (P < 0.001) over 7.0 (IQR, 3.0-11.0) years of follow-up observation. Each 1-SD lower natural log-transformed U/P urea ratio was independently associated with CKD progression (HR, 1.22 [95% CI, 1.12-1.33]) and incident KRT (HR, 1.22 [95% CI, 1.10-1.33]). Associations differed by baseline eGFR (P interaction = 0.009). Among those with an eGFR ≥30 mL/min/1.73 m, each 1-SD lower in ln(U/P urea ratio) was independently associated with CKD progression (HR, 1.30 [95% CI, 1.18-1.45]), but this was not significant among those with eGFR <30 mL/min/1.73 m (HR, 1.00 [95% CI, 0.84-1.20]).
Possibility of residual confounding. Single baseline 24-hour urine collection for U/P urea ratio.
In a large and diverse cohort of patients with common forms of CKD, U/P urea was independently associated with disease progression and incident kidney failure. Associations were not significant among those with advanced CKD at baseline.
尿/血浆(U/P)尿素比值与尿浓缩能力相关,并与常染色体显性多囊肾病的进展相关。作为一种拟议的肾小管功能生物标志物,我们假设 U/P 尿素比值也与更为常见的慢性肾脏病(CKD)形式的进展相关。
观察性队列研究。
美国共有 3723 名估计肾小球滤过率(eGFR)为 20-70 mL/min/1.73 m 的成年人,他们参与了慢性肾不全队列(CRIC)研究。
U/P 尿素比值,通过基线时的 24 小时尿液收集和血浆样本计算得出。
U/P 尿素比值与 eGFR 斜率、开始肾脏替代治疗(KRT)和 CKD 进展(定义为 eGFR 下降 50%或发生 KRT)之间的相关性。
多变量线性混合效应模型用于检验与 eGFR 斜率的关联。Cox 比例风险模型用于检验与二分类 CKD 结局的关联。
U/P 尿素比值的中位数为 14.8(IQR,9.5-22.2)。与 U/P 尿素比值最高五分位数的参与者相比,最低五分位数的参与者在 7.0(IQR,3.0-11.0)年的随访观察中,eGFR 每年下降 1.06 mL/min/1.73 m(P<0.001)。每 1-SD 较低的自然对数转换 U/P 尿素比值与 CKD 进展(HR,1.22 [95%CI,1.12-1.33])和发生 KRT(HR,1.22 [95%CI,1.10-1.33])独立相关。相关性因基线 eGFR 而异(P 交互=0.009)。在 eGFR≥30 mL/min/1.73 m 的患者中,ln(U/P 尿素比值)每降低 1-SD,与 CKD 进展独立相关(HR,1.30 [95%CI,1.18-1.45]),但在 eGFR<30 mL/min/1.73 m 的患者中,这并不显著(HR,1.00 [95%CI,0.84-1.20])。
可能存在残余混杂。用于 U/P 尿素比值的单一基线 24 小时尿液采集。
在一个由患有常见形式 CKD 的大量和多样化患者组成的队列中,U/P 尿素与疾病进展和新发肾衰竭独立相关。在基线时 CKD 已处于晚期的患者中,相关性不显著。